Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost adults with a BMI of 30 or above are within the licensed range for Mounjaro, and those with a BMI of 27 or above may also qualify if they have at least one weight-related health condition. That's the short answer. Whether Mounjaro is right for you specifically depends on a fuller clinical picture, assessed by a registered prescriber before any treatment begins. Mounjaro (tirzepatide) is a prescription-only medicine, so a prescriber — not an online form — makes the final call on suitability.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The quickest check you can do right now, in under a minute, is to run your height and weight through the NHS BMI calculator. That number sits at the centre of the licensed criteria. Mounjaro's UK licence covers adults with a BMI of 30 or above, and adults with a BMI between 27 and 29.9 who have at least one weight-related condition, things like hypertension, prediabetes, type 2 diabetes, obstructive sleep apnoea, raised cholesterol, or osteoarthritis.
If your background is South Asian, Chinese, Middle Eastern, Black African or African-Caribbean, guidance from NICE and NHS England recognises that health risks from excess weight tend to present at lower BMI values, so the thresholds shift down by 2.5 kg/m². A BMI of 27.5 or above, for instance, could bring you into scope where the standard figure would be 30.
A number on a calculator opens the door; it does not guarantee approval. A prescriber looks at the full picture. More on how BMI interacts with Mounjaro eligibility is worth reading if you're right on a threshold.
Some conditions actively support eligibility; others give a prescriber reason for caution. On the supportive side, the weight-related comorbidities listed in the licence (type 2 diabetes, hypertension, dyslipidaemia, sleep apnoea, cardiovascular disease) can make you eligible at a lower BMI and often mean Mounjaro addresses more than one health issue at once.
On the cautious side, there are conditions where tirzepatide is not recommended. A personal or close family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) means Mounjaro should not be used. A history of pancreatitis, certain gastrointestinal conditions, and diabetic retinopathy all require careful prescriber discussion rather than automatic exclusion. The NHS tirzepatide medicines page sets out the contraindications and interactions in plain language if you want to read ahead.
Kidney function, liver health, and any history of eating disorders are also factored in. None of this is to put barriers up, it's to make sure the medicine fits the person. If you're uncertain about a specific condition, our detailed guide to medical suitability for Mounjaro covers the most common scenarios.
Not every rejection is permanent, and not every clinic uses identical criteria. Some services apply NICE's NHS commissioning thresholds (BMI 35 or above, multiple comorbidities) even when offering private prescriptions, which is stricter than the licensed criteria actually require. If you've been told you're not eligible, it's worth understanding why that decision was made before assuming it applies everywhere.
Patients transferring from another provider, or already taking tirzepatide at a particular dose, follow a slightly different path at nume. Evidence of current treatment is requested, and any dose increase is reviewed clinically before it's approved. The aim is continuity without gaps, handled carefully. If you're already on treatment and thinking about moving, a quick read of the general FAQs covers the transfer process.
One thing that does not change between services: Mounjaro is a prescription-only medicine, and clinical assessment is required every time. A service skipping that step is not a shortcut worth taking.
Mounjaro became available on the NHS through a phased rollout following NICE's recommendation in December 2024. Early access is limited to people with high BMI and multiple qualifying comorbidities; the criteria broaden gradually through 2025 to 2027. For most people asking about suitability today, the realistic route is private prescription. A plain explanation of the NHS access process and who currently qualifies may be useful if you're weighing your options.
Private pricing varies by dose and provider. If cost is a consideration, the context around Mounjaro pricing in the UK explains what influences the figures and what a legitimate price typically includes. At nume, one price covers the consultation, prescription, the medicine, and free next-working-day delivery, no subscription, no hidden charges. Pricing is listed on the treatment page where you can also start your consultation.
Our prescribers review every consultation the same day it's submitted. If you'd like to find out where you stand, a structured eligibility check is a good first step, and the clinical team at nume is available for aftercare questions seven days a week once you're on treatment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.